DE69412251T2 - Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel - Google Patents

Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel

Info

Publication number
DE69412251T2
DE69412251T2 DE69412251T DE69412251T DE69412251T2 DE 69412251 T2 DE69412251 T2 DE 69412251T2 DE 69412251 T DE69412251 T DE 69412251T DE 69412251 T DE69412251 T DE 69412251T DE 69412251 T2 DE69412251 T2 DE 69412251T2
Authority
DE
Germany
Prior art keywords
virus
nitro compounds
tumor agents
aromatic nitro
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69412251T
Other languages
English (en)
Other versions
DE69412251D1 (de
Inventor
Ernest Kun
Jerome Mendeleyev
Eva Kirsten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of DE69412251D1 publication Critical patent/DE69412251D1/de
Application granted granted Critical
Publication of DE69412251T2 publication Critical patent/DE69412251T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69412251T 1993-05-12 1994-05-12 Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel Expired - Lifetime DE69412251T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6040993A 1993-05-12 1993-05-12
US08/076,313 US5464871A (en) 1993-05-12 1993-06-11 Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
PCT/US1994/005469 WO1994026730A2 (en) 1993-05-12 1994-05-12 Novel aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents

Publications (2)

Publication Number Publication Date
DE69412251D1 DE69412251D1 (de) 1998-09-10
DE69412251T2 true DE69412251T2 (de) 1999-01-07

Family

ID=26739885

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69412251T Expired - Lifetime DE69412251T2 (de) 1993-05-12 1994-05-12 Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel

Country Status (8)

Country Link
US (4) US5464871A (de)
EP (1) EP0698019B1 (de)
JP (1) JPH08510452A (de)
AT (1) ATE169296T1 (de)
AU (1) AU681889B2 (de)
CA (1) CA2162556A1 (de)
DE (1) DE69412251T2 (de)
WO (1) WO1994026730A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AU2604795A (en) * 1994-05-26 1995-12-21 New York Medical College Detection of halogenated precursors incorporated into dna
US6001555A (en) * 1994-09-23 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
WO1997008345A1 (en) * 1995-08-30 1997-03-06 New York Medical College Methods for labeling dna ends with halogenated nucleotides and detecting same with antibodies
US6511988B2 (en) 1997-04-10 2003-01-28 Isotechnika Inc. Activated iododerivatives for the treatment of cancer and aids
ATE307797T1 (de) 1997-04-10 2005-11-15 Isotechnika Inc Aktivierte iod-verbindungen zur behandlung von krebs und aids
US6306871B1 (en) 1998-04-10 2001-10-23 Randall W. Yatscoff Activated iododerivatives for the treatment of cancer and AIDS
BR9809115A (pt) 1997-05-13 2002-01-02 Octamer Inc Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) * 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2001275085A1 (en) 2000-06-01 2001-12-11 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
AU2001273099A1 (en) 2000-07-13 2002-01-30 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses
WO2002062293A2 (en) * 2001-02-02 2002-08-15 The Regents Of The University Of California Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
US7101676B2 (en) * 2002-01-11 2006-09-05 Douglas Buechter Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
CN102107008B (zh) * 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
ATE491437T1 (de) 2004-10-19 2011-01-15 Mpg Max Planck Ges Zur Foerderung Der Wissenschaften E V Formulierungen mit alkylphosphocholinen unter verwendung von neuen negativen ladungsträgern
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
JP5177429B2 (ja) * 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
AU2007217813A1 (en) * 2006-02-17 2007-08-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤を用いる疾病の治療方法
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
EP2059802A4 (de) * 2006-09-05 2010-09-08 Bipar Sciences Inc Verfahren für den entwurf von parp-hemmern und ihre verwendung
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
CN101190211B (zh) * 2006-11-23 2011-08-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用
NZ579098A (en) 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
EP2211854A4 (de) * 2007-10-19 2011-01-12 Bipar Sciences Inc Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
EP2250282A4 (de) * 2008-02-04 2011-05-18 Bipar Sciences Inc Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2012003563A1 (pt) * 2010-07-07 2012-01-12 Universidade Federal De Minas Gerais - Ufmg Composições farmacêuticas antineoplásicas contendo compostos nitroaromáticos substituídos
BR112013011135A2 (pt) 2010-11-05 2016-08-02 Zhejiang Hisun Pharm Co Ltd ''composto,método para a preparação do composto,composição farmacêutica e uso do composto''
US8586792B2 (en) 2011-12-28 2013-11-19 Divi's Laboratories Ltd. Process for the preparation of 4-iodo-3-nitrobenzamide
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
CN106366012A (zh) * 2016-08-25 2017-02-01 鲁南制药集团股份有限公司 一种制备4‑碘‑3‑硝基苯甲酰胺的方法
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) * 1954-02-16 X-amroo-zralkoxbbenzamdjes
US2006735A (en) * 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
US2003593A (en) 1935-02-23 1935-06-04 Duriron Co Heat exchanger
LU38172A1 (de) * 1957-11-25
US3161564A (en) * 1960-10-03 1964-12-15 Salsbury S Lab Dr Veterinary composition containing halo-nitro-benzamides and methods of using same
US3228833A (en) * 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
US4046767A (en) * 1970-09-03 1977-09-06 John Wyeth & Brother Limited Piperidino compounds
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4069331A (en) * 1974-05-16 1978-01-17 Boehringer Ingelheim Gmbh N-(p-fluorobenzoyl-n-propyl)-4-piperidylamides and salts thereof
DE3524542A1 (de) * 1985-07-10 1987-01-22 Hoechst Ag 1-oxa-3-oxo-4,8-diaza-spiro-(4,5)decan- verbindungen
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
GB8827850D0 (en) * 1988-11-29 1988-12-29 Shell Int Research Biocidal compounds
JPH05503073A (ja) * 1989-09-26 1993-05-27 オクタマー，インコーポレイテッド ウイルス性疾患の治療に有用な６―アミノ―１，２―ベンゾピロン
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5473074A (en) * 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
EP0609211A4 (de) 1991-10-22 1995-02-01 Octamer Inc Adenosin-diphosphoribose-polymerase bindende nitrosoaromatische verbindungen als antitumorale und antiretrovirale wirkstoffe.
WO1994009776A1 (en) 1992-11-02 1994-05-11 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-retroviral agents and anti-tumor agents
US6040993A (en) 1998-02-23 2000-03-21 Macronix International Co., Ltd. Method for programming an analog/multi-level flash EEPROM

Also Published As

Publication number Publication date
ATE169296T1 (de) 1998-08-15
EP0698019A1 (de) 1996-02-28
DE69412251D1 (de) 1998-09-10
CA2162556A1 (en) 1994-11-24
WO1994026730A2 (en) 1994-11-24
EP0698019B1 (de) 1998-08-05
US6004978A (en) 1999-12-21
AU6914494A (en) 1994-12-12
WO1994026730A3 (en) 1995-01-26
JPH08510452A (ja) 1996-11-05
AU681889B2 (en) 1997-09-11
US5464871A (en) 1995-11-07
US5652367A (en) 1997-07-29
US5670518A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
DE69412251T2 (de) Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel
ATE142876T1 (de) 5-iod-6-amino-1,2-benzopyrane und deren analoge
PL330407A1 (en) Substituted cyclopentane compounds useful as neuraminidaze inhibitors
NZ526088A (en) Urea substituted imidazoquinoline ethers
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
BR0011856A (pt) Agonistas de receptor a2a de n-pirazol
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR0013281A (pt) Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais
DE69932173D1 (de) Adenine-derivate
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
CY1105948T1 (el) Παραγωγα φαινυλακεταμιδο-θειαζολης, διepγασια για την παρασκευη τους και η χρηση τους ως παραγοντων κατα των ογκων
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
EA199901016A1 (ru) 9-оксим-производные эритромицина
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
EA200000847A1 (ru) Противоопухолевые средства
PT828721E (pt) 2-amino-benxoxazinonas para o tratamento de infeccoes virais
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
PT98976A (pt) Processo para a preparacao de heteroarilmetilbenzenos
IL138117A0 (en) 5-imino-13-deoxy anthracycline derivatives, their uses and processes for preparing them
DE60203740D1 (de) Luminacine analoge und deren verwendung
MX9709016A (es) 2-amino-benzoxazinonas, composiciones que las contienen y uso de las mismas.
ES2070087A1 (es) Derivados de indol
CY1113987T1 (el) Τροποποιημενα νουκλεοσιδια για τη θεραπεια ιικων μολυνσεων και του μη κανονικου κυτταρικου πολλαπλασιασμου

Legal Events

Date Code Title Description
8364 No opposition during term of opposition